A. Field of the Invention
The invention relates generally to wound treatment systems and methods, and more specifically to a system and method of treating a wound by combining ultrasonic debridement and reduced pressure therapy.
B. Description of Related Art
Wounds to the skin typically fall into two categories: chronic and acute. The natural healing mechanism in animals repairs acute wounds quickly by closing the wound, filling in lost tissue, and covering the wound with a new layer of skin. Those having observed wound healing in children often observe the healing of small acute wounds in a few days. Chronic wounds are often wounds in which the natural healing mechanisms have been impaired. Chronic wounds typically linger for extended periods of time and may never heal. Such wounds are often observed among the elderly or people suffering from diabetes. Another problem associated with wounds is infection. Infection is the invasion of a wound by pathogenic microorganisms or bacteria that grow within the wound, produce toxins, and subsequently injure the tissue surrounding the wound. To reduce the chance for infection of a wound, the wound is first cleaned to remove those microorganisms or bacteria that may have invaded the wound when it was created. Next, the wound typically is debrided or sterilized to remove nonviable or necrotic tissue and any microorganisms or bacteria resident within the wound. The third step in the treatment of a wound is to apply a dressing to cover the wound and promote its healing with the application of medication.
The debriding of a wound is often accomplished with mechanical surgical methods, referred to as sharps debridement. Specifically, the non-viable or necrotic tissue is cut from the wound and removed. Sometimes, surgical treatment of a wound will trigger the body's response to an acute wound and the wound will heal.
While the debridement process often involves cutting away tissue within the wound, recent efforts have involved the use of ultrasonic energy. A description of the use of ultrasonic energy and its use on skin appears in the following U.S. patents: Suroff, U.S. Pat. No. 4,040,414 (Ultrasonic Personal Care Instrument and Method); Beaty, et al., U.S. Pat. No. 5,312,329 (Piezo Ultrasonic and Electrosurgical Handpiece); Sakurai, et al., U.S. Pat. No. 5,391,144 (Ultrasonic Treatment Apparatus); Novak, et al., U.S. Pat. No. 6,171,265 (Handpiece for Use With a Multifunctional Operating Endoscopic Instrument); and in the following published PCT application: Babaev, WO 97/17933 (Method of Spraying A Surface Using Ultrasonic Radiation). Further descriptions are found in the following articles: King, et al., Burns, Vol. 22, No. 4, Pg. 307, (Debridement of Burn Wounds with a Surgical Ultrasonic Aspirator); Vanderburgh, et al., Gynecologic Oncology, Vol. 39, Pg. 103 (1990); (Debridement of Vaginal Radiation Ulcers Using the Surgical Ultrasonic Aspirator); and Herte, et al., Am. Society of Plastic and Reproductive Surgeons Prelim. Rpt. (November 1978); (Comparative Wound Healing in Animal Subjects Using the Cavitron Ultrasonic Surgical Aspirator vs. Conventional Surgical Instrument).
Further, in recently issued U.S. Pat. No. 6,916,296 to Soring, et al., entitled System for Antiseptic Surgery, a system using ultrasound was proposed for wound healing. Specifically, a device called a sonotrode is placed in a liquid within the wound. The sonotrode generates ultrasonic vibrations and cavitations in the liquid that leads to destruction of the bacteria cells. Specifically, the high level of energy released in the fluid kills the bacteria cells by rupturing their cell walls. While U.S. Pat. No. 6,916,296 reports a significant reduction in germ count in a wound, it is also taught that high levels of energy can be used for very short periods of time, or that lower levels of energy can be used for longer periods of time—up to several minutes.
In practice, the use of ultrasound to debride wounds involves relatively high amounts of ultrasonic energy typically applied in a focused manner to energize a relatively small area of a wound for a short period of time. The area over which ultrasonic energy is broadcast at any given time is typically less than about 5 cm2. Since the treatment is focused, the ultrasonic energy is typically only applied for less than about 60 seconds to any specific area.
Following debridement, wounds are dressed to cover the wound and promote healing. In recent years, it has been found that the application of reduced pressure to a wound promotes healing in many cases. This is particularly evident in chronic wounds, such as those that develop in elderly patients, but may also occur in any type of wound. Studies have also revealed that frequent irrigation of a wound helps promote healing by aiding in the removal of wound exudate, unwanted bioburden, and optionally, serving as an effective vehicle for the application & delivery of medication. Examples of wound treatment systems employing some of these techniques are found in the following U.S. patents: Zamierowski, U.S. Pat. No. 4,969,880 (Wound Dressing and Treatment Method); Zamierowski, U.S. Pat. No. 5,100,396 (Fluidic Connection System and Method); Zamierowski, U.S. Pat. No. 5,261,893 (Fastening System and Method); Zamierowski, U.S. Pat. No. 5,527,293 (Fastening System and Method); Argenta, et al., U.S. Pat. No. 5,636,643 (Wound Treatment Employing Reduced Pressure); Argenta, et al., U.S. Pat. No. 5,645,081 (Method of treating tissue damage and apparatus for same); Zamierowski, U.S. Pat. No. 6,071,267 (Medical Patient Fluid Management Interface System and Method); Vogel, et al., U.S. Pat. No. 6,135,116 (Method for Treating Ulcers); and Hunt, et al., U.S. Pat. No. 6,142,982 (Portable wound treatment apparatus).
While ultrasonic debridement has been taught as a way of initially clearing a wound of nonviable or necrotic tissue, the procedure has not gained acceptance as part of broad-based system for accelerating healing of a wound, in part due to the labor-intensive process involved with traditional ultrasonic debridement. A need currently exists for a system that utilizes ultrasonic energy at low energy levels over a prolonged period of time to debride a wound. For ease of use and improvement in performance, the application area over which the ultrasonic energy is applied should be relative large compared to existing procedures, which call for a more focused beam. Also needed is a system that employs a non-focused, low energy debridement procedure such as ultrasound, with reduced pressure therapy, and optionally, with a system providing fluid irrigation and removal of debrided tissue.
All of the patents, patent applications, and other publications referenced herein are incorporated by reference to the maximum extent allowable by law.
The problems presented by wound treatment systems tissue dressings are solved by the systems and methods of the present invention. In accordance with one embodiment of the present invention, a wound treatment system is provided that includes a distribution manifold, a reduced pressure source, and an ultrasonic energy transducer. The reduced pressure source is fluidly connected to the distribution manifold to deliver reduced pressure to a tissue site, and the ultrasonic energy transducer is positioned adjacent to the distribution manifold.
In accordance with another embodiment of the present invention, a wound treatment system for debriding and healing a wound site includes a distribution manifold, a reduced pressure source fluidly connected to the distribution manifold, an acoustically-conducting membrane, and an ultrasonic energy transducer. The acoustically-conducting membrane is positioned between the distribution manifold and the wound site, and the ultrasonic energy transducer is coupled to the membrane.
In still another embodiment of the present invention, a wound treatment system includes means for dressing a wound, means for reducing pressure at the wound, and means for debriding the wound.
In accordance with yet another embodiment of the present invention, an ultrasonic wound treatment system for treating a wound site includes an ultrasonic energy transducer configured to deliver ultrasonic energy to substantially all of the wound site at a power level less than about 1 W/cm2. The ultrasonic energy is delivered during a selected duration such that substantially all of the wound site is exposed to ultrasonic energy for at least ten minutes per day (10 min/day).
In yet another embodiment of the present invention, a wound treatment system includes a distribution manifold configured to be placed in fluid communication with a wound. A fluid source is fluidly connected to the distribution manifold and configured to deliver a fluid to the wound during a first selected duration. An ultrasonic energy transducer is configured to be placed in ultrasonic communication with and deliver ultrasonic energy to the wound during a second selected duration. A reduced pressure source is fluidly connected to the distribution manifold and configured to deliver a reduced pressure to the wound during a third selected duration.
In accordance with another embodiment of the present invention, a method for treating a wound includes simultaneously applying reduced pressure and ultrasonic energy to the wound to debride and heal the wound.
In still another embodiment of the present invention, a method for treating a wound includes delivering a fluid to the wound and allowing the fluid to dwell at the wound for a selected duration. Ultrasonic energy is applied to the wound during the selected duration, and a reduced pressure is applied to the wound following the selected duration to remove the fluid and any debrided tissue.
In another embodiment of the present invention, a multipurpose wound dressing includes a distribution manifold that is configured to distribute a reduced pressure to a wound site. An ultrasonic energy transducer is positioned adjacent to the distribution manifold to provide ultrasonic debridement to the wound site.
In yet another embodiment of the present invention, a multipurpose wound dressing includes a distribution manifold configured to distribute a reduced pressure to a wound site. An acoustically-conducting membrane is positioned on a tissue contact side of the distribution manifold and is configured to contact the wound site. An ultrasonic energy transducer is operatively coupled to the acoustically-conducting membrane.
Other objects, features, and advantages of the present invention will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.
Referring to
Referring more specifically to
The multipurpose wound dressing 11 includes a distribution manifold 20, an ultrasonic energy transducer 50, a tube 42 for fluidly communicating with the distribution manifold, and, optionally, a drape 30. The distribution manifold 20 is configured to be placed adjacent to the wound site 100. The distribution manifold 20 includes a plurality of flow channels or pathways to facilitate the distribution of reduced pressure or fluids to or from the wound site. In one embodiment the distribution manifold 20 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam such as GranuFoam manufactured by Kinetic Concepts, Inc. of San Antonio, Tex. If an open-cell foam is used, the porosity may vary, but is preferably about 400 to 600 microns.
The drape 30 is positioned over the distribution manifold 20 when an open wound site is treated to seal and isolate the wound site. If the wound site being treated is a subcutaneous or deep tissue wound site, drape 30 may not be necessary to maintain reduced pressure at the wound site. Drape 30 may be any biocompatible, flexible material. Drape 30 may be impermeable or semi-permeable to liquid, gas, or both depending upon a given application. A reduced pressure applicator 40 is placed under the drape 30 and over the distribution manifold 20. The tube 42 is fluidly connected at a distal end to the applicator 40 and is fluidly connected at a proximal end to the reduced pressure source 12, which may be a pump or a wall suction outlet. Near the reduced pressure source 12, the tube 42 is schematically represented as reduced pressure delivery tube 42a. The reduced pressure source is capable of supplying reduced pressure to the wound through the reduced pressure delivery tube 42a and distribution manifold 20. While the applicator 40 provides one means of transferring reduced pressure from the reduced pressure delivery tube 42a to distribution manifold 20, applicator 40 may be omitted if the reduced pressure delivery tube 42a is placed in direct fluid communication with distribution manifold 20.
A fluid delivery tube 42b may be provided to deliver a fluid to the wound and may similarly be fluidly connected to the distribution manifold by the applicator 40. The representation of tubes 42, 42a, and 42b in
The ultrasonic energy transducer 50 may include a frequency generator and an amplifier and is used to transmit ultrasonic energy to the wound site 100. The ultrasonic energy transducer may be a piezoelectric transducer or a surface wave acoustic device. In
The distribution manifold 20 acts as a transmission medium to relay ultrasonic energy to the wound site 100. When a reticulated foam is used, the transmission efficiency of the foam may be enhanced by using the fluid delivery source to infuse the foam with water, aqueous and sub-aqueous solutions, or gels. The presence of fluid within the foam improves the ability of the foam to transfer the ultrasonic energy. In this regard, the distribution manifold performs both the functions of a manifold and a transmission medium for ultrasonic energy. It should further be noted that gels or other transmission enhancing substances may be placed within or on the distribution manifold 20. For example, a gel may be placed between the distribution manifold 20 and the wound site 100 prior to the transmission of ultrasonic energy through the distribution manifold 20 to enhance energy transmission.
The amount of ultrasonic energy being applied to the wound by the ultrasonic energy transducer 50 is less than that of traditional ultrasonic debridement transducers. Preferably, if a high frequency (about 800 to 4000 kHz to) transducer is used, the power applied to the transducer is about 1.0 W/cm2, and more preferably about 0.5 W/cm2. If a low frequency (about 20 to 120 kHz to) transducer is used, the power applied to the transducer preferably is about 0.5 W/cm2, and more preferably about 0.1 W/cm2.
Referring to
In operation, the multipurpose dressing described herein combines reduced pressure therapy, ultrasonic debridement, and optional fluid delivery for debriding, cleaning, and healing the wound site. All of these functions may be integrated into a combined system that provides for the intermittent or continuous operation of each function individually or simultaneously, without changing the dressing between functions. Since the dressing is intended to remain in place for several days between changes, the ultrasonic energy transducer is optimized to provide debridement over long time periods at low power.
In one exemplary operational example, an irrigation or medicinal fluid is delivered by the fluid delivery source 14 to the distribution manifold during a first selected duration. Preferably, the first selected duration is about five (5) minutes. During this duration, the fluid is allowed to permeate the distribution manifold 20 and irrigate the wound site 100. During a second selected duration following the first selected duration, the fluid is allowed to dwell at the wound site and ultrasonic energy is transmitted to the wound site 100 by the ultrasonic energy transducer. The ultrasonic energy debrides the wound of nonviable and necrotic tissue. Preferably, the second selected duration is about fifteen minutes (15), or about three times the first selected duration. Following the second selected duration, transmission of ultrasonic energy is ceased, and reduced pressure is applied through the distribution manifold by the reduced pressure source. The reduced pressure removes the delivered fluid from the wound and distribution manifold, as well as wound exudate and debrided tissue. The application of reduced pressure continues for a third selected duration, which is preferably about forty (40) minutes, or about three times the second selected duration. The exemplary time durations described above may vary, and each of the procedures (i.e. fluid delivery, ultrasonic debridement, and reduced pressure therapy) may be performed independently of one another, or simultaneously with one or both of the other procedures.
It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
This application claims the benefit of U.S. Provisional Application No. 60/761,289, filed Jan. 23, 2006, which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4040414 | Suroff | Aug 1977 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielson | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt et al. | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4982730 | Lewis, Jr. | Jan 1991 | A |
4985019 | Michelson | Jan 1991 | A |
5016615 | Driller et al. | May 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5312329 | Beaty et al. | May 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5391144 | Sakurai et al. | Feb 1995 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5524624 | Tepper et al. | Jun 1996 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5626554 | Ryaby et al. | May 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6171265 | Novak et al. | Jan 2001 | B1 |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6916296 | Soring et al. | Jul 2005 | B2 |
7128719 | Rosenberg | Oct 2006 | B2 |
7410469 | Talish et al. | Aug 2008 | B1 |
7500956 | Wilk | Mar 2009 | B1 |
7569742 | Haggstrom | Aug 2009 | B2 |
20020055693 | Thompson et al. | May 2002 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020115952 | Johnson et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020156400 | Babaev | Oct 2002 | A1 |
20030040687 | Boynton et al. | Feb 2003 | A1 |
20030212351 | Hissong et al. | Nov 2003 | A1 |
20040030304 | Hunt et al. | Feb 2004 | A1 |
20040077977 | Ella et al. | Apr 2004 | A1 |
20050020966 | Soring et al. | Jan 2005 | A1 |
20060241533 | Geller | Oct 2006 | A1 |
20090264807 | Haggstrom | Oct 2009 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Apr 1999 | AU |
755496 | Feb 2002 | AU |
2005436 | Jun 1990 | CA |
43 06 478 | Sep 1994 | DE |
29504378 | Sep 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1 219 278 | Jul 2002 | EP |
1018967 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
1574066 | Sep 1980 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 333 965 | Aug 1999 | GB |
2 329 127 | Aug 2000 | GB |
4129536 | Apr 1992 | JP |
2003-515424 | May 2003 | JP |
2112571 | Jun 1998 | RU |
2175539 | Nov 2001 | RU |
2261692 | Oct 2005 | RU |
71559 | Apr 2002 | SG |
587941 | Jan 1978 | SU |
1461466 | Feb 1989 | SU |
WO 8002182 | Oct 1980 | WO |
WO 8704626 | Aug 1987 | WO |
WO 9010424 | Sep 1990 | WO |
WO 9309727 | May 1993 | WO |
WO 9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9717933 | May 1997 | WO |
WO 9718007 | May 1997 | WO |
WO 9913793 | Mar 1999 | WO |
Number | Date | Country | |
---|---|---|---|
20070239078 A1 | Oct 2007 | US |
Number | Date | Country | |
---|---|---|---|
60761289 | Jan 2006 | US |